Arcadia Biosciences Receives U.S. Patent for High Fiber Wheat with Improved Yield
— Latest patent expands the company’s portfolio to include an allele that improves yield in high fiber, resistant starch wheat —
DAVIS, Calif. (Feb. 27, 2020) – Arcadia Biosciences, Inc., (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced the U.S. Patent and Trademark Office has awarded the company a patent for a yield-improving allele for high fiber, resistant starch wheat. This innovation, which represents the latest patent in Arcadia’s GoodWheat™ portfolio of non-genetically modified (non-GM) wheat varieties, was developed through ArcaTech, the company’s proprietary technology platform.
“The invention of this higher-yielding high fiber wheat allele further demonstrates our commitment to enhancing the strength of our improved wheat platform,” said Matthew Plavan, president and CEO of Arcadia Biosciences. “We continue to bring valuable and nutritional innovation to wheat – and ultimately consumers – through our partnership with Bay State Milling and Arista Cereal Technologies, which brings our high fiber resistant starch bread wheat to market in North America under Bay State’s HealthSense™ brand portfolio.”
Multi-year field studies conducted by Arcadia found that wheat breeding lines carrying the higher-yielding allele produced an average of 6 to 9 percent higher yields, with some resulting in as much as 30 percent higher yields. Field trials further indicated there may be other benefits to this innovation, including reduction in sensitivity to the damaging effects of cold at specific growth stages. As example, wheat carrying the allele produced 25 percent higher yield than wheat without the allele when plots were damaged by frost at the very sensitive heading stage.
The higher-yielding allele is the output of Arcadia’s ArcaTech technology platform and is the latest among a suite of patents Arcadia has licensed to Arista Cereal Technologies and Bay State Milling in North America. These improvements to the crop yield and production efficiency are an example of the companies’ continuing plans to expand the adoption and market footprint of high fiber, resistant starch wheat.
For more information about Arcadia’s GoodWheat portfolio of specialty wheat ingredients, visit www.arcadiabio.com.
About Arcadia Biosciences, Inc.
Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. Arcadia’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. The company’s new GoodHemp seed catalog delivers genetically superior hemp seeds, clones, transplants, flower and extracts, applying the company’s proprietary crop innovation technology, ArcaTech, to an emerging crop. For more information, www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected additional benefits of this yield-improving allele. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ and affiliates’ ability to develop and sell commercial products incorporating their traits, and complete the regulatory review process for such products; Arcadia’s compliance with laws and regulations that impact Arcadia’s business, and changes to such laws and regulations;, and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2018 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
Chief Financial Officer
LinkedIn: Arcadia Biosciences